Geoffrey Pitzer, MD
Otolaryngology · la Mesa, CANPI 1770673238
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Optinose US, Inc. at 33.5% of the total. Reporting peaked in 2024 at $7,139 and has fallen 54.8% since, to $3,225 in 2025. Among otolaryngology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $83.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$6K
- Sanofi$4K
- Smith+Nephew$3K
- Stryker$2K
- GSK$581
- Haag-streit USA, Inc.$301
- plus $2K from 22 others
Across 171 payments — averaging $1879.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$147K
- Biohaven Pharmaceutical Holding Company Ltd.$79K
- GSK$59K
- Optinose US, Inc.$35K
What the payments were for
- Consulting fees$3,18018%
- Speaking & faculty fees$4,60026%
- Travel & lodging$2,43214%
- Food & beverage$7,16541%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 55 | $5,840 |
| Sanofi | 17 | $4,068 |
| Smith+Nephew | 9 | $2,795 |
| Stryker | 46 | $2,214 |
| GSK | 25 | $581 |
| Haag-streit USA, Inc. | 2 | $301 |
| Medtronic | 10 | $292 |
| AstraZeneca | 3 | $255 |
| Regeneron Healthcare Solutions, Inc. | 10 | $252 |
| Neurent Medical Limited | 3 | $114 |
| Pfizer | 2 | $110 |
| Davol Inc. | 4 | $97 |
| Resmed Corp | 1 | $67 |
| Intersect ENT, Inc. | 4 | $61 |
| Aerin Medical Inc. | 2 | $47 |
| Merz North America, Inc. | 2 | $41 |
| KARL Storz Endoscopy-america | 1 | $38 |
| Integra Lifesciences Corporation | 2 | $36 |
| Arrinex, Inc. | 1 | $33 |
| Aroa Biosurgery Incorporated | 1 | $31 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Hospira, Inc. | 1 | $28 |
| Paratek Pharmaceuticals, Inc. | 1 | $25 |
| Merck | 1 | $25 |
| Amgen | 1 | $25 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Acera Surgical, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xhance$4,839
- Coblation$2,216
- TULA$2,216
- DUPIXENT$539
- CLARIFIX CRYOTHERAPY DEVICE$504
- TRIGEN$493
- TEZSPIRE$230
- ENTELLUS - XPRESS ENT DILATION SYSTEM$160
- NUCALA$119
- XPRESS ENT DILATION SYSTEM$104
How this compares
$17,444 in reported general payments places this provider in the 95th percentile of 1,021 otolaryngology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XhanceFluticasone Propionate | 45 | $49,502 |
| Azelastine Hcl | 327 | $8,388 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 44 | $4,900 |
| Fluticasone Propionate | 262 | $2,926 |
| Ipratropium Bromide | 98 | $2,877 |
| Omeprazole | 78 | $1,230 |
| Fluocinolone Acetonide Oil | 25 | $813 |
| Famotidine | 87 | $750 |
| Doxycycline Monohydrate | 24 | $557 |
| Clotrimazole | 15 | $519 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 25 | $342 |
| Pantoprazole Sodium | 57 | $282 |
| Mupirocin | 27 | $219 |
| Montelukast Sodium | 16 | $213 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $5,840 | $49,50245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,021 otolaryngology providers in California.
Other otolaryngology in la Mesa
- Brian WeeksSan Diego$924K
- Randall OwRoseville$613K
- Amir MoradiVista$389K
- Keith BlackwellLos Angeles$349K
- Kalpna DurairajSun Valley$348K
- Todd MillerNewport Beach$259K
- Jeffrey SuhLos Angeles$223K
- Dennis TangLos Angeles$209K
- Jeffrey FeinfieldThousand Oaks$160K
- Jonathan SykesGranite Bay$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.